NASDAQ · MNOV
Medicinova Inc
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for MNOV: Nov 11, 2026
Medicinova Inc Common Stock is estimated to report earnings on 11/11/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.06. The reported EPS for the same quarter last year was $-0.06.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.06 | $-0.06 | $-0.06 | 2 |
| Dec 2026 | $-0.09 | $-0.07 | $-0.11 | 2 |
| Mar 2027 | $-0.08 | $-0.08 | $-0.08 | 1 |
| Jun 2027 | $-0.11 | $-0.11 | $-0.11 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Fintel · Zacks- RTTNews · Sep 28, 6:49 AM EDTMediciNova Reports Phase 2 MN-001 Data In T2DM-Associated NAFLD; Stock Plunges In Premarket(RTTNews) – MediciNova, Inc. (MNOV) announced topline results from the Phase 2 MN-001-NATG-202 study evaluating MN-001 in patients with hypertriglyceridemia and non-alcoholic fatty liver disease associated with type 2 diabetes mellitus (T2DM).
- RTTNews · Sep 24, 10:32 AM EDTMNOV Stock In Focus As COMBAT-ALS Completes Double-Blind Phase; Results Due By Year-End(RTTNews) – MediciNova, Inc. (MNOV) announced completion of the last patient, last visit in the double-blind portion of the Phase 2b/3 COMBAT-ALS trial evaluating MN-166 (ibudilast) in patients with amyotrophic lateral sclerosis (ALS).
- RTTNews · Sep 18, 4:36 AM EDTBiotech Stocks At 52-Week Highs – MNOV +36%, PBLS +10%, ABCL +9%, HAE, NEO(RTTNews) – The following biotech stocks reached a 52-week high on September 17, 2026, driven by the gain on certain clinical or financial results.
- Fintel · Sep 17, 12:07 PM EDTRoth Capital Initiates Coverage of MediciNova with Buy RatingFintel reports that on September 17, 2026, Roth Capital initiated coverage of MediciNova (NASDAQGM:MNOV) with a Buy recommendation. Prior to this rating action, the stock closed at $2.52 on September 16, 2026. This latest close follows a price change of +40.78% over one week from
- RTTNews · Sep 16, 6:16 AM EDTCan MediciNova's Upcoming MN-166 And MN-001 Readouts Change The Investment Narrative?(RTTNews) – Key Points
- RTTNews · Sep 16, 1:21 AM EDTBiotech Stocks At 52-Week Highs – MNOV +8%, RVTY +8%, TXG +6%, TLX +9%, SDGR +12%(RTTNews) – The following biotech stocks reached a 52-week high on September 15, 2026, driven by the gain on certain clinical or financial results.
- Zacks · Aug 13, 6:50 PM EDTMediciNova (MNOV) Reports Q2 Loss, Tops Revenue EstimatesMediciNova (MNOV) delivered earnings and revenue surprises of +16.67% and +205.63%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 12, 6:15 PM EDTMaxCyte, Inc. (MXCT) Reports Q2 Loss, Beats Revenue EstimatesMaxCyte (MXCT) delivered earnings and revenue surprises of +33.33% and +11.86%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 6, 7:10 PM EDTAlector (ALEC) Reports Q2 Loss, Tops Revenue EstimatesAlector (ALEC) delivered earnings and revenue surprises of +12.50% and +283.37%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · May 27, 4:46 AM EDTMediciNova Concludes Phase 2 For MN-001 In Treating Diabetic Non-Alcoholic Fatty Liver Disease(RTTNews) – MediciNova Inc. (MNOV), a clinical-stage biopharmaceutical company, on Tuesday announced the completion of the last patient, last visit in its Phase 2 trial of MN-001 for hypertriglyceridemia and non-alcoholic fatty liver disease associated with type-2 diabetes mellit
- Fintel · Mar 16, 8:03 PM EDTHC Wainwright & Co. Initiates Coverage of MediciNova (MNOV) with Buy RecommendationFintel reports that on March 16, 2026, HC Wainwright & Co. initiated coverage of MediciNova (NasdaqGM:MNOV) with a Buy recommendation. Analyst Price Forecast Suggests 603.40% Upside
- Fintel · Feb 26, 2:55 AM ESTMediciNova (MNOV) Price Target Increased by 11.11% to 10.20The average one-year price target for MediciNova (NasdaqGM:MNOV) has been revised to $10.20 / share. This is an increase of 11.11% from the prior estimate of $9.18 dated February 1, 2026. The price target is an average of many targets provided by analysts. The
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Medicinova Inc from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.